FK960

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530316

CAS#: 133920-70-4 (free)

Description: FK-960, also known as FK-59960, is a drug potentially for the treatment of Alzheimer's disease (AD). FK962 is also a novel enhancer of somatostatin release, which exerts cognitive-enhancing actions in rats. FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats. FK960 ameliorates the memory deficits in rats through a novel mechanism of action.

Chemical Structure

img
FK960
CAS# 133920-70-4 (free)
Instruction

Theoretical Analysis

MedKoo Cat#: 530316
Name: FK960
CAS#: 133920-70-4 (free)
Chemical Formula: C13H16FN3O2
Exact Mass: 265.12
Molecular Weight: 265.288
Elemental Analysis: C, 58.86; H, 6.08; F, 7.16; N, 15.84; O, 12.06

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 133920-70-4 (free)   208186-69-0 (hydrate)    

Synonym: FK-960; FK960; FK960; FK-59960; FK 59960; FK59960.

IUPAC/Chemical Name: N-(4-Acetyl-1-piperazinyl)-4-fluorobenzamide

InChi Key: XTOKQKWTUYYVAO-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H16FN3O2/c1-10(18)16-6-8-17(9-7-16)15-13(19)11-2-4-12(14)5-3-11/h2-5H,6-9H2,1H3,(H,15,19)

SMILES Code: O=C(NN1CCN(C(C)=O)CC1)C2=CC=C(F)C=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 133920-70-4 (FK-960 Free) 208186-69-0 (FK-960 hydrate)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 265.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tokita K, Inoue T, Yamazaki S, Wang F, Yamaji T, Matsuoka N, Mutoh S. FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol. 2005 Dec 19;527(1-3):111-20. PubMed PMID: 16325809.

2: Koyama Y, Egawa H, Osakada M, Baba A, Matsuda T. Increase by FK960, a novel cognitive enhancer, in glial cell line-derived neurotrophic factor production in cultured rat astrocytes. Biochem Pharmacol. 2004 Jul 15;68(2):275-82. PubMed PMID: 15193999.

3: Doggrell SA. The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease. Expert Opin Investig Drugs. 2004 Jan;13(1):69-72. Review. PubMed PMID: 14680454.

4: Wang F, Matsuoka N, Mutoh S, Kaneko S. Modulation of Ca2+ channel currents by a novel antidementia drug N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960) in rat hippocampal neurons. J Pharmacol Exp Ther. 2004 Jan;308(1):120-6. PubMed PMID: 14569070.

5: Noda A, Takamatsu H, Matsuoka N, Koyama S, Tsukada H, Nishimura S. Effect of N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), an antidementia drug with a novel mechanism of action, on regional cerebral blood flow and glucose metabolism in aged rhesus macaques studied with positron emission tomography. J Pharmacol Exp Ther. 2003 Jul;306(1):213-7. PubMed PMID: 12676883.

6: Tada H, Uchino M, Nagai K, Nomura T, Kondoh T, Saito N, Yamamura T, Yajima Y, Nishizaki T. The anti-dementia drug FK960 stimulates glial glutamate release via a PKA pathway. Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):63-8. PubMed PMID: 12531516.

7: Noda A, Takamatsu H, Murakami Y, Yajima K, Tatsumi M, Ichise R, Nishimura S. Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys. J Nucl Med. 2003 Jan;44(1):105-8. PubMed PMID: 12515883.

8: Moriguchi A, Nakano K, Yamaguchi I, Sano K, Noda K, Hashimoto M, Ohara K, Matsuoka N, Goto T. FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats. Brain Res. 2002 Dec 27;958(2):381-9. PubMed PMID: 12470874.

9: Tokita K, Yamazaki S, Yamazaki M, Matsuoka N, Mutoh S. Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol Biochem Behav. 2002 Oct;73(3):511-9. PubMed PMID: 12151024.

10: Tozaki H, Kanno T, Nomura T, Kondoh T, Kodama N, Saito N, Aihara H, Nagata T, Matsumoto S, Ohta K, Nagai K, Yajima Y, Nishizaki T. Role of glial glutamate transporters in the facilitatory action of FK960 on hippocampal neurotransmission. Brain Res Mol Brain Res. 2001 Dec 16;97(1):7-12. PubMed PMID: 11744157.

11: Hodgkiss JP, Kelly JS. Effect of FK960, a putative cognitive enhancer, on synaptic transmission in CA1 neurons of rat hippocampus. J Pharmacol Exp Ther. 2001 May;297(2):620-8. PubMed PMID: 11303051.

12: Inoue T, Wang F, Moriguchi A, Shirakawa K, Matsuoka N, Goto T. FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7. PubMed PMID: 11172755.

13: Matsuyama S, Nomura T, Nishizaki T. Sustained facilitatory action of FK960 on hippocampal neurotransmission. Brain Res. 2000 Feb 28;857(1-2):317-20. PubMed PMID: 10700585.

14: Tsukada H, Yamazaki S, Noda A, Inoue T, Matsuoka N, Kakiuchi T, Nishiyama S, Nishimura S. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, restores the regional cerebral blood flow response abolished by scopolamine but not by HA-966: a positron emission tomography study with unanesthetized rhesus monkeys. Brain Res. 1999 Jun 19;832(1-2):118-23. PubMed PMID: 10375657.

15: Matsuoka N, Satoh M. FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices. Brain Res. 1998 Jun 1;794(2):248-54. PubMed PMID: 9622644.

16: Matsuoka N, Aigner TG. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine. J Pharmacol Exp Ther. 1997 Mar;280(3):1201-9. PubMed PMID: 9067304.

17: Yamazaki M, Matsuoka N, Maeda N, Ohkubo Y, Yamaguchi I. FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action. J Pharmacol Exp Ther. 1996 Dec;279(3):1157-73. PubMed PMID: 8968337.